Considering this meta-analysis was based on a limited amount of data, however, further studies are still warranted to evaluate the impact of KRAS mutation on the efficacy of ICIs in patients with advanced NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.